Lilly begins world's first study of a potential COVID-19 antibody treatment in humans

Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.

This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.

from Breaking World Pharma News https://ift.tt/38gcuwp